Abstract: GSK2606414 is a potent, selective, first-in-class small-molecule inhibitor of the protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK), a central sensor of the integrated stress response (ISR). While the ISR is an evolutionarily conserved network that maintains cellular homeostasis under stress, its chronic activation is implicated in various pathologies, including cancer, vascular diseases, and neurodegeneration. In the context of oncology, GSK2606414 has demonstrated significant anti-tumor and anti-angiogenic activities by disrupting the PERK-mediated adaptation of cancer-associated fibroblasts and tumor cells to the stressful tumor microenvironment. Beyond oncology, the compound exhibits protective effects in preclinical models of atherosclerosis, restenosis, thrombosis, and multiple neurodegenerative disorders by mitigating pathological ISR overdrive. However, the clinical translation of GSK2606414 is currently hindered by significant limitations, including dose-dependent pancreatic toxicity, broad off-target kinase binding (such as RIPK1 inhibition), and paradoxical ISR activation at high concentrations. Future therapeutic development relies on biomarker-guided patient stratification, the design of highly selective next-generation analogues, and targeted delivery systems to widen the therapeutic index.
1. Introduction
The integrated stress response (ISR) is a highly conserved intracellular signaling network that coordinates translational control in response to diverse environmental and cellular stresses, such as proteotoxicity, nutrient deprivation, and oxidative stress [1][2]. At the core of this pathway is the phosphorylation of the eukaryotic translation initiation factor 2 alpha (eIF2α), which attenuates global protein synthesis while selectively upregulating stress-adaptive transcription factors like ATF4 and CHOP [1][2]. One of the primary kinases responsible for eIF2α phosphorylation is the PKR-like endoplasmic reticulum kinase (PERK), which acts as a sensor for endoplasmic reticulum (ER) stress [1].
GSK2606414 (chemically identified as 7-methyl-5-(1-{[3-(trifluoromethyl) phenyl] acetyl}-2,3-dihydro-1 H-indol-5-yl)-7 H-pyrrolo [2,3-d] pyrimidin-4-amine) was discovered as a potent and selective first-in-class inhibitor of PERK [1]. By blocking PERK activity, GSK2606414 prevents the downstream consequences of chronic ISR activation. Consequently, it has been extensively utilized as a pharmacological tool compound to investigate the role of the ISR across multiple disease models, showing particular promise in oncology, vascular pathophysiology, and neurodegeneration [1][2].
2. Pharmacological Activity
Oncology and Cancer Research: Sustained PERK activity facilitates tumor growth and pathological neovascularization. In pancreatic ductal adenocarcinoma, prolonged serum deprivation activates a PERK-p-eIF2α-ERK1/2 signaling cascade in cancer-associated fibroblasts (CAFs). This cascade drives endothelial-mesenchymal transition (EndoMT), allowing CAFs to incorporate into the tumor vasculature. Pharmacological inhibition with GSK2606414 markedly reduces micro-vessel density and suppresses tumor growth [1]. Furthermore, GSK2606414 suppresses the activity of peptidyl-glycine α-amidating mono-oxygenase (PAM), an enzyme whose PERK-dependent activation fosters tumor migration and angiogenesis [1]. Interestingly, in head and neck squamous cell carcinoma, GSK2606414 has been shown to enhance reovirus infection via an ATF4-dependent mechanism, suggesting utility in oncolytic viral therapies [1].
Vascular Diseases: GSK2606414 exhibits robust protective effects in cardiovascular models. It mitigates atherosclerosis by inhibiting trimethylamine-N-oxide (TMAO)-induced EndoMT and apoptosis, and by reducing oxidized low-density lipoprotein (ox-LDL) and Angiotensin II-evoked endothelial cell death [1]. In models of restenosis and thrombosis, GSK2606414 reduces the intima-to-media ratio, preserves luminal area, lowers the expression of thrombogenic tissue factor (CD142), and enhances post-angioplasty re-endothelialization while suppressing pro-inflammatory cytokines like IL1-β, IL6, and VCAM1 [1].
Neurodegeneration: In the central nervous system, chronic ISR activation is a convergent pathomechanism. Oral administration of GSK2606414 (e.g., 50-150 mg/kg twice daily) achieves brain-level exposures that prevent neurodegeneration, ameliorate brain atrophy, and improve motor and cognitive functions in models of tauopathy (such as the rTg4510 mouse model), prion disease, Parkinson's disease, and Marinesco-Sjögren syndrome [2]. Localized infusion into the CA1 region of the hippocampus has also been shown to enhance memory and reverse age-related cognitive deterioration [2].
3. Molecular Mechanism of Action
GSK2606414 functions as an ATP-competitive inhibitor of the PERK kinase domain [1][2]. Under conditions of ER stress, the accumulation of misfolded proteins causes the dissociation of the chaperone GRP78 from PERK, leading to PERK homodimerization and autophosphorylation. Active PERK then phosphorylates eIF2α [1]. By binding to PERK, GSK2606414 halts this phosphorylation event, thereby releasing the translational brake and preventing the induction of downstream stress-adaptive or pro-apoptotic genes, such as ATF4 and CHOP [1][2].
In the tumor microenvironment, this mechanism disrupts the PERK-p-eIF2α-ERK1/2 axis in CAFs and uncouples PERK from PAM activation, effectively starving the tumor of necessary angiogenic and migratory signals [1]. In vascular endothelium, GSK2606414 blocks the CNPY2/PERK/CHOP cascade and the non-canonical cGAS-STING-PERK pathway, preventing stress-induced endothelial apoptosis and inflammation [1]. However, the mechanism is highly context-dependent; while inhibiting PERK is beneficial in these states, the compound can paradoxically activate the ISR via the GCN2 kinase at micromolar concentrations, leading to dose-dependent pathway rewiring [2].
4. Structure-Activity Relationship (SAR)
GSK2606414 is a synthetic small molecule characterized by a pyrrolo[2,3-d]pyrimidin-4-amine core linked to an indoline derivative (7-methyl-5-(1-{[3-(trifluoromethyl) phenyl] acetyl}-2,3-dihydro-1 H-indol-5-yl)-7 H-pyrrolo [2,3-d] pyrimidin-4-amine) [1]. It was optimized to act as an ATP-competitive inhibitor targeting the kinase domain of PERK. While it exhibits nanomolar potency against PERK, its structural features also permit binding to the ATP-binding pockets of several other kinases, which dictates both its primary efficacy and its off-target liability profile at higher systemic concentrations [1][2].
5. Current Limitations
Despite its robust preclinical efficacy, the translational potential of GSK2606414 is severely restricted by its safety and selectivity profile:
Systemic Toxicity: High systemic exposures of GSK2606414 are associated with severe on-target and off-target toxicities, most notably pancreatic and exocrine toxicity, body weight loss, and hyperglycemia [1][2]. The secretory nature of the pancreas makes it highly reliant on basal PERK activity to manage physiological ER stress, rendering it highly susceptible to PERK ablation [2].
Off-Target Kinase Inhibition: GSK2606414 exhibits broad kinase-binding activity. It has been identified as a potent inhibitor of RIPK1. At concentrations below 1 μM, it significantly inhibits c-kit, Aurora B kinase, BRK, MLK2, c-MER, DDR2, MLCK2, and IKKe. At concentrations around 1 μM, it further inhibits TRKA/B/C, MLK1/3, RET, LCK, NEK4, KHS, AXL, YES, and WNK2 [1].
Paradoxical ISR Activation: At micromolar tissue levels—often required to ensure saturated target binding in vivo—GSK2606414 can induce directional ambiguity by activating the ISR through an alternative kinase, GCN2, complicating the interpretation of biomarker directionality and therapeutic outcomes [2].
6. Future Perspectives
The preclinical validation of GSK2606414 establishes the PERK-ISR axis as a highly promising therapeutic target in oncology, vascular disease, and neurodegeneration. However, future clinical translation requires overcoming its current limitations through several strategies [1][2]:
Next-Generation Modulators: There is a critical need for the rational design of novel allosteric compounds or inhibitors targeting specific domains (e.g., the kinase insert loop of PERK) to preserve on-target benefits while minimizing pancreatic toxicity and off-target multikinase liabilities [1][2].
Targeted Delivery Systems: To widen the therapeutic index, advanced delivery technologies such as lipid nanoparticles, liposomes, or specialized local delivery tools (e.g., post-angioplasty local delivery or intracranial infusion) must be developed. These platforms can restrict exposure to the tumor microenvironment, vascular lesions, or specific neural circuits, thereby bypassing systemic exocrine toxicity [1][2].
Biomarker-Guided Translation: Future clinical trials must employ rigorous biomarker gating. Monitoring target engagement markers (such as p-eIF2α and ATF4 directionality) will be essential to select patient populations with demonstrable ISR overdrive and to ensure that the chosen dosing regimens do not trigger paradoxical ISR activation [2].
